NeurAxis Announces Closing of $5.0 Million Registered Direct Offering
NeurAxis (NYSE: NRXS) has successfully closed a registered direct offering of 1,538,461 shares of common stock at $3.25 per share, raising approximately $5.0 million in gross proceeds. The company also secured over $1 million from warrant exercises in the same week. This financing follows the recent FDA clearance expanding indications for IB-Stim treatment of Pediatric Functional Abdominal Pain (FAP). The company plans to implement a CPT Category I code effective January 1, 2026. Craig-Hallum Capital Group served as the exclusive placement agent for the offering, which was conducted under a shelf registration statement previously filed with the SEC.
NeurAxis (NYSE: NRXS) ha completato con successo un'offerta diretta registrata di 1.538.461 azioni ordinarie a 3,25 dollari per azione, raccogliendo circa 5 milioni di dollari di proventi lordi. Nella stessa settimana, la società ha inoltre incassato oltre 1 milione di dollari dall'esercizio di warrant. Questo finanziamento segue la recente approvazione della FDA che amplia le indicazioni per il trattamento IB-Stim del Dolore Addominale Funzionale Pediatrico (FAP). L'azienda prevede di implementare un codice CPT Categoria I a partire dal 1° gennaio 2026. Craig-Hallum Capital Group ha agito come agente di collocamento esclusivo per l'offerta, condotta nell'ambito di una dichiarazione di registrazione a scaffale precedentemente depositata presso la SEC.
NeurAxis (NYSE: NRXS) ha cerrado con éxito una oferta directa registrada de 1.538.461 acciones comunes a 3,25 dólares por acción, recaudando aproximadamente 5 millones de dólares en ingresos brutos. Además, la compañía aseguró más de 1 millón de dólares por el ejercicio de warrants en la misma semana. Esta financiación sigue a la reciente aprobación de la FDA que amplía las indicaciones para el tratamiento IB-Stim del Dolor Abdominal Funcional Pediátrico (FAP). La empresa planea implementar un código CPT Categoría I efectivo a partir del 1 de enero de 2026. Craig-Hallum Capital Group actuó como agente exclusivo de colocación para la oferta, que se realizó bajo una declaración de registro en estantería previamente presentada ante la SEC.
NeurAxis (NYSE: NRXS)는 1,538,461주의 보통주를 주당 3.25달러에 등록 직접 공모를 성공적으로 마무리하여 약 500만 달러의 총 수익을 확보했습니다. 같은 주에 회사는 워런트 행사로부터 100만 달러 이상을 추가로 확보했습니다. 이번 자금 조달은 소아 기능성 복통(FAP) 치료를 위한 IB-Stim 적응증 확대에 대한 FDA의 최근 승인에 따른 것입니다. 회사는 2026년 1월 1일부터 CPT 카테고리 I 코드를 도입할 계획입니다. Craig-Hallum Capital Group이 독점 배치 에이전트로서 이번 공모를 진행했으며, 이는 이전에 SEC에 제출된 선반 등록 명세서에 따라 이루어졌습니다.
NeurAxis (NYSE : NRXS) a clôturé avec succès une offre directe enregistrée de 1 538 461 actions ordinaires à 3,25 $ par action, levant environ 5 millions de dollars de produits bruts. La société a également obtenu plus de 1 million de dollars provenant de l'exercice de bons de souscription au cours de la même semaine. Ce financement fait suite à la récente approbation de la FDA élargissant les indications du traitement IB-Stim pour la douleur abdominale fonctionnelle pédiatrique (FAP). La société prévoit de mettre en place un code CPT de catégorie I à compter du 1er janvier 2026. Craig-Hallum Capital Group a agi en tant qu'agent de placement exclusif pour cette offre, réalisée dans le cadre d'une déclaration d'enregistrement en étagère précédemment déposée auprès de la SEC.
NeurAxis (NYSE: NRXS) hat erfolgreich ein registriertes Direktangebot von 1.538.461 Stammaktien zu 3,25 USD pro Aktie abgeschlossen und dabei rund 5,0 Millionen USD Bruttoerlös erzielt. Das Unternehmen sicherte sich zudem in derselben Woche über 1 Million USD aus der Ausübung von Warrants. Diese Finanzierung folgt auf die kürzliche FDA-Zulassung zur Erweiterung der Indikationen für die IB-Stim-Behandlung bei pädiatrischen funktionellen Bauchschmerzen (FAP). Das Unternehmen plant die Einführung eines CPT-Kategorie-I-Codes ab dem 1. Januar 2026. Craig-Hallum Capital Group fungierte als exklusiver Platzierungsagent für das Angebot, das unter einer zuvor bei der SEC eingereichten Shelf-Registrierung durchgeführt wurde.
- Secured $5.0 million in gross proceeds from direct offering
- Additional $1 million obtained from warrant exercises
- Recent FDA clearance expanding IB-Stim treatment indications
- CPT Category I code implementation planned for January 2026
- Share dilution due to issuance of 1,538,461 new shares
- Offering price of $3.25 per share may represent a discount to market price
Insights
NeurAxis strengthens financial position with $5M offering while expanding FDA-approved treatment indications, positioning for revenue growth.
NeurAxis has successfully completed a
The timing of this capital raise aligns strategically with two key catalysts: the recent FDA clearance expanding the company's IB-Stim treatment to include Pediatric Functional Abdominal Pain (FAP) and the upcoming implementation of a CPT Category I code effective January 1, 2026. The CPT Category I code is particularly significant as it typically facilitates more streamlined insurance reimbursement compared to temporary codes, potentially accelerating revenue growth.
What makes this development particularly compelling is the expanded indication for IB-Stim in a treatment area with limited FDA-approved options. The company specifically notes there are no FDA-approved drug therapies for children suffering from these abdominal pain disorders linked to gut-brain interaction, giving NeurAxis a potentially valuable market position.
The financing strengthens NeurAxis's ability to commercialize its neuromodulation therapies while the expanded FDA clearance broadens the addressable market. With these developments, the company appears positioned to drive revenue growth in 2025-2026, though investors should monitor quarterly results to confirm execution against this opportunity.
Strengthens Balance Sheet and Provides Growth Capital
CARMEL, Ind., May 22, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing chronic and debilitating conditions in children and adults, today announced the closing of its previously announced registered direct offering of 1,538,461 shares of its common stock at a purchase price of
“This financing, along with the recent FDA clearance expanding indications for IB-Stim treatment of Pediatric Functional Abdominal Pain (FAP), marks a significant milestone for NeurAxis,” said Brian Carrico, President and Chief Executive Officer of NeurAxis. “The
Craig-Hallum Capital Group acted as the exclusive placement agent for the offering.
A shelf registration statement on Form S-3 (File No. 333-283798) relating to the securities offered was originally filed with the U.S. Securities and Exchange Commission (the “SEC”) on December 13, 2024, and declared effective on February 11, 2025. The offering was made only by means of a prospectus supplement and accompanying prospectus that form a part of the shelf registration statement. The final prospectus supplement and accompanying prospectus relating to the offering were filed with the SEC and are available on the SEC’s website at www.sec.gov. Electronic copies of the final prospectus supplement and accompanying prospectus may be obtained on the SEC’s website at www.sec.gov or by contacting Craig-Hallum Capital Group LLC at 323 North Washington Avenue, Suite 300, Minneapolis, Minnesota 55401, Attention: Equity Capital Markets, by telephone at 612-334-6300, or by email at prospectus@chlm.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NeurAxis, Inc.
NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive adoption of its IB-Stim™ therapy, which is its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim™ is FDA cleared for functional abdominal pain associated with irritable bowel syndrome (IBS) in adolescents 8-21 years old. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.
Forward-Looking Statements
Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, the results of the shareholder vote to enable the issuance of the Preferred Stock, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.
For more information, please visit http://neuraxis.com.
For contraindications, precautions, warnings, and IFU, please see: https://ibstim.com/important-information/.
Contacts:
Company
NeurAxis, Inc.
info@neuraxis.com
Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com
FAQ
How much did NeurAxis (NRXS) raise in their May 2025 offering?
What is the purpose of NeurAxis (NRXS) $5 million offering?
What recent FDA clearance did NeurAxis (NRXS) receive?
Who was the placement agent for NeurAxis (NRXS) May 2025 offering?
When will NeurAxis (NRXS) implement its CPT Category I code?
